PA-MONROL
24.11.2021 08:02:04 CET | Business Wire | Press release
Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) today announced their agreement with Molecular Targeting Technologies, Inc. (MTTI), a clinical stage biotech company focused on developing innovative therapies for rare cancers, for the supply of the medical radioisotope no-carrier-added 177 Lu (n.c.a. 177 Lu).
Eczacıbaşı-Monrol entered the theranostic market in 2019 as one of the few producers of Lutetium-177 worldwide and since then has provided an uninterrupted supply of this critical product to patients in many countries. In line with its mission to improve the quality of life of cancer patients globally, the company is establishing strategic partnerships with international pharmaceutical companies and constructing a new production facility compliant with FDA 21 CFR Part 211 quality standards that will have an annual capacity of 60 thousand doses. Thanks to its location close to Istanbul's transportation hub, the new facility will benefit from a worldwide logistics network and agreements with cargo services to 320 destinations worldwide.
Aydin Küçük, General Manager of Eczacıbaşı-Monrol, noted that n.c.a.177 Lu contributes to the company's mission of adding value to human life with leading and innovative approaches in the diagnosis and treatment of critical diseases and added, "To support our growth in this field, we're establishing a new GMP certified facility exclusively for theranostic R&D and production with a new technology that will enable us to maximize our supply of high-quality Lutetium. Sustainability and innovation are two of our core values, and we strive for continuous improvement in our operations and products while trying to serve patients all around the world."
Molecular Targeting Technologies, Inc. (MTTI) CEO, Chris Pak said, " We’ve identified a timely and sustainable supply of a key therapeutic ingredient needed for the development and launch of our lead asset 177 Lu-EBTATE and other EB platform technologies. We are excited to start
this collaboration and build what promises to be a great relationship with a reliable and trusted radioisotope supply partner like Eczacıbaşı-Monrol for the supply of n.c.a.177 Lu.”
About Molecular Targeting Technologies, Inc. (MTTI)
Molecular Targeting Technologies, Inc. is a privately held, rapidly growing, well financed, clinical stage biotech developing targeted radiotherapeutics and diagnostics for rare cancers. We are committed to building value by acquiring and translating innovative imaging, radiopharmaceutical and theranostic assets to improve human health, reduce healthcare costs and reward stakeholders. MTTI expects to be orchestrating multiple clinical trials in 2022. For more information: www.mtarget.com
; www.evathera.com
About Eczacıbaşı-Monrol
Eczacıbaşı-Monrol Nuclear Products Co. is an innovative, international supplier of radiopharmaceuticals for diagnosis and treatment in nuclear medicine. Eczacıbaşı-Monrol is headquartered in Istanbul and delivers customer-oriented service globally.
Monrol exports high quality and a wide spectrum of nuclear medicine products to more than 50 countries around the globe and has manufacturing sites and operational projects in different regions. For more information visit www.monrol.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211123006032/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cyclic Materials Appoints Tomasz Poznar as Chief Commercial Officer to Accelerate Global Commercial Growth16.7.2026 15:20:00 CEST | Press release
Industry leader in critical materials and battery recycling to drive Cyclic’s global commercial growth and strategic partnerships. Cyclic Materials, the rare earth recycling company building a circular supply chain for rare earth elements and critical materials, today announced the appointment of Tomasz Poznar, Ph.D., as Chief Commercial Officer. The appointment strengthens Cyclic Materials’ executive team as the company accelerates commercial expansion across North America, Europe, and Asia. Most recently, Poznar served as Chief Commercial Officer at Ascend Elements, where he led the company’s global commercial strategy, strategic partnerships, and business development. During his tenure, he helped secure more than USD $1.5 billion in commercial agreements, including a landmark USD $1 billion supply agreement with a major global automaker, while also supporting approximately USD $320 million in TCTF government funding that accelerated the company’s growth in North America and Europe.
Modon Holding and Nammos Hotels & Resorts Bring Nammos Ras El Hekma to Egypt’s North Coast16.7.2026 14:50:00 CEST | Press release
Developed in partnership with Nammos Hotels & Resorts, the landmark Mediterranean destination will bring together branded residences, a luxury resort, restaurant and beach club, retail village, and signature dining and wellness experiences to Egypt for the first time. Abu Dhabi-based Modon Holding and Nammos Hotels & Resorts have announced Nammos Ras El Hekma – the renowned lifestyle and hospitality brand’s first fully integrated destination in Egypt. Located within the Wadi Yemm precinct, the development will bring Ras El Hekma’s promise of timeless Mediterranean living to life, combining Nammos Residences, Nammos Resort, Nammos Village, and a curated selection of all-day dining and wellness experiences, including the globally renowned Nammos Restaurant & Beach Club. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716740934/en/ Modon Holding and Nammos Hotels & Resorts bring Nammos Ras El Hekma to Egypt’s North Coast (Pho
Tridiagonal.ai (T.AI) Partners with PETRONAS Carigali’s TriCipta AI with IBM to Advance Engineering Domain-Driven AI Solutions for Upstream Operations16.7.2026 14:30:00 CEST | Press release
Tridiagonal.ai will contribute engineering domain-driven AI solutions, physics-informed models and Decision Intelligence capabilities to support upstream surface equipment optimisation, maintenance reliability and asset integrity decision workflows. Tridiagonal.ai Pvt. Ltd. (T.AI), the dedicated AI arm of Tridiagonal Group, announced its role in the third Joint Development Agreement (JDA) involving PETRONAS Carigali Sdn. Bhd. and IBM Malaysia Sdn. Bhd. to advance PETRONAS Carigali’s flagship TriCipta AI across the Upstream value chain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260715579933/en/ Signing ceremony for the third TriCipta AI Joint Development Agreement, attended by executives from Tridiagonal.ai (T.AI), PETRONAS Carigali, and IBM Malaysia. TriCipta AI is PETRONAS Carigali’s partnership model that combines deep domain technical expertise with advanced AI technology experts to accelerate the development and dep
Crown Bioscience Joins C-Path's NAMs Developer Coalition to Advance Human-Relevant Models in Drug Development16.7.2026 14:30:00 CEST | Press release
Global CRO brings patient-derived models, organoid platforms and biomarker expertise to collaborative effort advancing regulatory acceptance of New Approach Methodologies Crown Bioscience is a global contract research organization (CRO) specializing in oncology drug discovery and development, today announced it has joined Critical Path Institute's (C-Path) New Approach Methodologies Developer Coalition (NAMs-DC), a collaborative initiative dedicated to advancing the validation, qualification and regulatory adoption of innovative human-relevant research methods. Crown Bioscience joins a growing community of technology developers, pharmaceutical companies, regulatory stakeholders and scientific experts working to accelerate the adoption of New Approach Methodologies (NAMs) across drug discovery and development. Through its participation in NAMs-DC, Crown Bioscience will contribute expertise spanning patient-derived xenograft (PDX) models, patient-derived tumor organoids, ex vivo patient
Silo Communications expands fiber connectivity in rural Illinois with Adtran16.7.2026 14:00:00 CEST | Press release
News summary: Silo Communications needed a scalable fiber access platform to bring faster, more reliable broadband to underserved communities With Adtran’s technology and intelligent software, Silo Communications is strengthening service delivery as it evolves from wireless to fiber Deployment supports wider state and federal efforts to close the digital divide and create a foundation for long-term rural growth Adtran today announced that Silo Communications, a rural broadband provider based in northern Illinois, is using its fiber access portfolio and software applications to expand high-speed connectivity for underserved homes and businesses. As demand for reliable broadband continues to grow across communities, Silo Communications is building on its wireless heritage with a scalable fiber network designed to support higher speeds, stronger service reliability and future expansion. The deployment supports wider state and federal efforts to extend high-speed connectivity to underserve
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom